Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.
Latest Information Update: 13 Dec 2023
At a glance
- Drugs Envafolimab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Oct 2023 Status changed to active, no longer recruiting, according to Results presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress, All enrolled patients have finished induction chemotherapy treatment, the study is ongoing. Further follow-up is needed to confirm the long-term efficacy. Long-term efficacy is awaited.
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress